Omnitrope Injection is a form of synthetic human growth hormone used to treat growth hormone deficiency in children and adults. It helps promote normal growth in children with short stature and supports metabolic functions in adults with hormone imbalances. This medication is often prescribed when natural growth hormone levels are insufficient and is used as part of a comprehensive treatment plan that may include diet and exercise.

Omnitrope works by replacing or supplementing the body’s natural growth hormone. It stimulates growth in bones and muscles by enhancing protein synthesis, increasing the production of insulin-like growth factor-1 (IGF-1), and promoting fat breakdown. These effects improve overall growth, muscle strength, and energy metabolism. The injection also supports bone mineralization and helps regulate blood sugar levels, contributing to better physical health and development.

This medication should not be used in individuals with active cancer, tumors, or known hypersensitivity to growth hormone products. It is also contraindicated in cases where growth plates have closed or in patients with acute critical illness such as respiratory failure or post-surgical complications. Careful monitoring is advised for those with diabetes, thyroid disorders, or cardiovascular issues. Regular follow-ups are essential to ensure the treatment is safe and effective, and to avoid complications like abnormal bone growth or swelling.

Some common side effects include injection site reactions such as redness or pain, headaches, and muscle stiffness. Others may experience swelling, joint discomfort, or water retention. In rare cases, it can cause changes in blood sugar levels, thyroid hormone imbalances, or increased pressure inside the skull. Patients should be monitored for unusual symptoms like excessive growth, vision changes, or breathing difficulties, and should report them immediately to their healthcare provider.

Omnitrope is generally not recommended during pregnancy, as its effects on the developing fetus have not been fully established. Use should be limited to cases where the benefits clearly outweigh potential risks, and only under close medical supervision. For breastfeeding mothers, it is uncertain whether the medication passes into breast milk. Therefore, it should only be used when necessary, and the health of both mother and baby should be carefully monitored throughout the treatment period.

Store this medication in a refrigerator at 36°F to 46°F (2°C to 8°C). Keep all medicines out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Omnitrope (somatropin) package insert. Princeton, NJ: Sandoz, Inc.; 2016 Dec.
2. Genotropin (somatropin) package insert. New York, NY: Pharmacia & Upjohn Company; 2016 Dec.
3. Food and Drug Administration (US FDA) Drug Safety Communication. Safety review update of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death. Retrieved August 4, 2011. Available on the WorldWide Web at: http://www.f– LinkOpens in New Tab
4. Albertsson-Wikland K, Martensson A, Savendalh L, et al. Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. J Clin Endocrinol Metab. 2016; 101: 2149-2159.
5. Humatrope (somatropin) package insert. Indianapolis, IN: Eli Lilly and Company; 2016 Dec.
6. Serostim (somatropin) package insert. Rockland, MA: EMD Serono, Inc.; 2017 May.
7. Nutropin (somatropin) package insert. San Francisco, CA: Genentech; 2016 Dec.
8. Accretropin (somatropin) package insert. Winnipeg, Canada: Cangene Corporation; 2016 Dec.
9. Nutropin AQ (somatropin) package insert. San Francisco, CA: Genentech; 2016 Dec.
10. Saizen (somatropin) package insert. Rockland, MA: EMD Serono Inc; 2017 May.
11. Norditropin (somatropin) package insert. Plainsboro, NJ: Novo Nordisk; 2016 Dec.
12. Zomacton (somatropin) package insert. Parsippany, NJ: Ferring Pharmaceuticals, Inc; 2016 Dec.
13. Zorbtive (somatropin) injection package insert. Rockland, MA: EMD Serono, Inc.; 2017 May.
14. Cook DM, Yuen KC, Biller BM, et al; American Association of Clinical Endocrinologists (AACE). American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and
15. The American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227-46.